Non-Small Cell Lung Cancer (NSCLC)

>

Latest News

Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC
Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC

April 23rd 2025

The phase 3 HARMONi-6 trial found invonescimab plus chemotherapy improved PFS vs tislelizumab plus chemotherapy in squamous NSCLC.

3 Things You Should Know About Unresectable NSCLC
3 Things You Should Know About Unresectable NSCLC

April 21st 2025

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC
Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

April 20th 2025

Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC
Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC

April 18th 2025

Phase 3 CROWN trial findings suggest that patients with ALK-positive NSCLC may maintain efficacy even after reducing lorlatinib dosing to mitigate AEs.
Elucidating Lorlatinib Benefit, ALK TKI Sequencing in ALK-Positive NSCLC

April 14th 2025